ライフサイエンスコーパス: second-line chemotherapy

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 e interviewed in relation to both first- and second-line chemotherapy).

2 We also analysed the second-line chemotherapy.

3 eritoneal lymph node dissection (RPLND), and second-line chemotherapy.

4 many as 20% to 30% of patients never receive second-line chemotherapy.

5 time that a solid tumor had been cured with second-line chemotherapy.

6 e treated at Indiana University with VeIP as second-line chemotherapy.

7 s as surrogates for OS in patients receiving second-line chemotherapy.

8 irst-line chemotherapy and 47 in relation to second-line chemotherapy (15 patients were interviewed i

9 or markers after first-line (50 patients) or second-line chemotherapy (64 patients) who underwent PCR

10 clinical trial end points, the prevalence of second-line chemotherapy administration, the role of tre

11 uperior to survival previously reported with second-line chemotherapy, and is similar to the results

12 25 levels less than 35 U/mL after initial or second-line chemotherapy, and relapsed more than 6 month

13 year with the approval of a vaccine therapy, second-line chemotherapy, and reported survival advantag

14 ourse is also acceptable, with initiation of second-line chemotherapy at disease progression.

15 mised-controlled trials suggest a benefit of second-line chemotherapy compared with supportive care a

16 Second-line chemotherapy consisted of paclitaxel 135 mg/

17 e younger, can be successfully salvaged with second-line chemotherapy followed by allogeneic stem cel

18 col encompassing dose-dense and dose-intense second-line chemotherapy, followed by HDT and ASCT, are

19 emoglobin </= 11.0 g/dL, receiving first- or second-line chemotherapy for metastatic breast cancer, w

20 For patients without progression, timing of second-line chemotherapy for optimum clinical benefit re

21 Second-line chemotherapy for patients with oesophagogast

22 combination with ifosfamide and cisplatin as second-line chemotherapy for patients with relapsed test

23 urgery, secondary or interval cytoreduction, second-line chemotherapy, hormonal therapy, and immunoth

24 and ixabepilone each have modest activity as second-line chemotherapy in docetaxel-refractory castrat

25 The addition of high-dose CBX to second-line chemotherapy in NSCLC cannot be recommended.

26 boplatin is increasingly used as initial and second-line chemotherapy of ovarian cancer and other mal

27 ine chemotherapy v 43%, n = 20 being offered second-line chemotherapy; P = .006).

28 at first-line chemotherapy v 43%, n = 20 at second-line chemotherapy; P = .06).

29 Salvage therapy was successful with second-line chemotherapy/radiation and autologous stem-c

30 or PFS and OS, adverse factors were use of a second-line chemotherapy regimen and interval of more th

31 ing ifosfamide, carboplatin, etoposide (ICE) second-line chemotherapy (SLT) followed by high-dose the

32 Women offered second-line chemotherapy were more likely to undergo che

33 mary refractory aggressive NHL who underwent second-line chemotherapy with ICE with the intent of adm

34 ary refractory aggressive NHL should receive second-line chemotherapy, with the intent of administeri

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。